Palsonify
Coverage of Palsonify in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for $10 billion, gaining access to Palsonify, a drug for acromegaly, and other drug candidates. The deal marks Vertex's largest acquisition as it expands beyond its cystic fibrosis portfolio.
- Vertex Pharmaceuticals is buying Crinetics to expand into rare hormonal diseases
Vertex Pharmaceuticals is acquiring Crinetics to expand into rare hormonal diseases. The deal provides access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia.
- STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, gaining access to its drug Palsonify for acromegaly and other drug candidates. The acquisition, valued at $85 per share, caused Crinetics' shares to rise 101% in after-hours trading.